Lynx1 Capital Management »

Foghorn Therapeutics shares owned by Lynx1 Capital Management

Quarter-by-quarter ownership of Foghorn Therapeutics (FHTX) shares owned by Lynx1 Capital Management from 13F filings

Historical chart of Lynx1 Capital Management investment in Foghorn Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Foghorn Therapeutics held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Foghorn Therapeutics by Lynx1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $301k 62k 4.88

More positions owned by Lynx1 Capital Management

Cullinan Oncology (CGEM)
Stoke Therapeutics (STOK)
Agios Pharmaceuticals (AGIO)
C4 Therapeutics Com Stk (CCCC)
Korro Bio (KRRO)
Tscan Therapeutics (TCRX)
Precision Biosciences Com New (DTIL)
Neuphoria Therapeutics (NEUP)
Passage Bio Com New (PASG)
Cg Oncology (CGON)
Pliant Therapeutics (PLRX)
Entrada Therapeutics (TRDA)
Vyne Therapeutics (VYNE)
Traws Pharma Com New (TRAW)
Foghorn Therapeutics (FHTX)

View all positions for Lynx1 Capital Management

Top funds holding Foghorn Therapeutics

Flagship Ventures Management
FMR
BVF
Deerfield Management Company
Raymond James Financial
BlackRock
Euclidean Capital
Vanguard Capital Management
Geode Capital Management
Siren
State Street Corporation
Ameriprise Financial
Renaissance Technologies
Candriam Luxembourg S.C.A.
Vanguard Portfolio Management

View all funds holding Foghorn Therapeutics